Table 1.
Clinical and biochemical features of older women with osteoporosis and Vertebral Fracture (VF) and osteoporosis with No Vertebral Fractures (NVFs) participating in the study
| Variables | VF | NVF | p‐value |
|---|---|---|---|
| Sample size | (n = 24) | (n = 12) | |
| Age (years) | 81.46 4 | 81.4 3.1 | 1 |
| Race | .104 | ||
| White | 7 (29.2%) | 7 (58.3%) | |
| No white | 14 (58.3%) | 5 (41.7%) | |
| Asian | 3 (12.5%) | 0 (0%) | |
| Height (cm) | 147.4 ± 5.9 | 146.0 ± 3.1 | .365 |
| Weight (kg) | 61.1 ± 11.8 | 57.2 ± 10.4 | .339 |
| BMI (kg/m2) | 28.1 ± 5.2 | 26.8 ± 4.6 | .468 |
| Alcohol (≥3U/day), % | 4 (16.7%) | 2 (16.7%) | 1 |
| Smoking or ex‐smoking (%) | 3 (12.5%) | 1 (8.3%) | 1 |
| Physical activity | .771 | ||
| Low | 5 (20.8%) | 3 (25%) | |
| Moderate | 15 (62.5%) | 8 (66.7%) | |
| High | 4 (16.7%) | 1 (8.3%) | |
| Fall (≥1/year), % | 5 (20.8%) | 3 (25%) | 1 |
| Osteoporosis family history (%) | .379 | ||
| No | 15 (62.5%) | 10 (83.3%) | |
| Yes | 3 (12.5%) | 1 (8.3%) | |
| Unknown | 6 (25%) | 1 (8.3%) | |
| Fracture family history (%) | .192 | ||
| No | 16 (66.7%) | 11 (91.7%) | |
| Yes | 1 (4.2%) | 0 (0%) | |
| Unknown | 7 (29.2%) | 1 (8.3%) | |
| Diabetes Mellitus (%) | 3 (12.5%) | 3 (25%) | .378 |
| Hypertension (%) | 19 (79.2%) | 11 (91.7%) | .64 |
| Heart attack (%) | 3 (12.5%) | 1 (8.3%) | 1 |
| Stroke (%) | 2 (8.3%) | 0 (0%) | .543 |
| Dyslipidemia (%) | 11 (45.8%) | 7 (58.3%) | .48 |
| Calcium supplement use (%) | 10 (41.7%) | 6 (50%) | .635 |
| Vitamin D supplement use (%) | 15 (62.5%) | 6 (50%) | .473 |
| Bisphosphonates use (%) | 11 (45.8%) | 5 (41.7%) | .813 |
| Creatinine (mg/dl) | 0.8 (0.73–1.09) | 0.79 (0.62–0.89) | .47 |
| Total calcium (mg/dl) | 9.6 (9.5–9.8) | 9.6 (9.3–9.98) | .853 |
| Total phosphorus (mg/dl) | 3.6 (3.2–3.78) | 3.5 (3.15–3.68) | .479 |
| Alkaline phosphatase (U/L) | 81 (61.75–94.25) | 68.5 (62.25–86.75) | .557 |
| 25OHD (ng/ml) | 23.5 ± 6.8 | 19.0 ± 9.0 | .101 |
| iPTH (pg/dl) | 57.3 ± 22.3 | 60.1 ± 14.3 | .696 |
| CTX (ng/ml) | 0.27 ± 0.16 | 0.33 ± 0.19 | .303 |
| P1NP (ng/ml) | 36.65 (17.95–48.55) | 38.75 (22.9–58.83) | .505 |
| Lumbar spine BMD (g/cm2) | 0.77 ± 0.11 | 0.77 ± 0.15 | .956 |
| Lumbar spine T‐score | −2.89 ± 1.08 | −2.79 ± 1.05 | .804 |
| Total hip BMD (g/cm2) | 0.71 ± 0.11 | 0.70 ± 0.08 | .862 |
| Total hip T‐score | −2.13 ± 0.81 | −2.02 ± 0.62 | .701 |
| Femoral neck BMD (g/cm2) | 0.57 ± 0.10 | 0.59 ± 0.06 | .663 |
| Femoral neck T‐score | −2.60 ± 0.74 | −2.42 ± 0.57 | .477 |
The Kolmogorov‐Smirnov test was used to evaluate the normal distribution. The values of p are for comparisons of means (Student's t‐test or Mann‐Whitney test) or proportions (Chi‐square test, Fisher's test, or likelihood ratio test). Values of p < .05 were considered significant.
Abbreviations: 25OHD, 25‐hydroxyvitamin D; BMD, bone mineral density; BMI, body mass index; iPTH, intact parathyroid hormone.